Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADiTx Therapeutics

1.54
+0.10006.94%
Post-market: 1.550.0087+0.56%19:56 EDT
Volume:91.51K
Turnover:138.76K
Market Cap:3.26M
PE:0.00
High:1.56
Open:1.44
Low:1.44
Close:1.44
Loading ...

BRIEF-Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO Of Adimune, And Chris Mitton, President Of Pearsanta, Will Join Aditxt Weekly Update On June 6

Reuters
·
05 Jun

Saundra Pelletier, Evofem Biosciences’ CEO, DR. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

THOMSON REUTERS
·
05 Jun

BRIEF-Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt

Reuters
·
30 May

Appili Therapeutics Inc -Entitled to Receive $1 Mln Termination Fee From Aditxt

THOMSON REUTERS
·
30 May

Aditxt to Scrap Merger Deal With Appili Therapeutics

MT Newswires Live
·
19 May

BRIEF-Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics

Reuters
·
19 May

Aditxt Inc. Terminates Arrangement Agreement with Appili Therapeutics, Eliminating $16M in Obligations

Reuters
·
19 May

Aditxt Inc - Termination to Eliminate About $16 Mln in Closing Obligations

THOMSON REUTERS
·
19 May

Aditxt Inc - Termination Effective May 31, 2025

THOMSON REUTERS
·
19 May

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

THOMSON REUTERS
·
19 May

Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01

Reuters
·
15 May

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Business Wire
·
02 May

Aditxt Inc Withdraws April 14 Release That Said Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

THOMSON REUTERS
·
18 Apr

Aditxt Inc Withdraws April 14 Release and Says No Replacement Release Will Be Issued

THOMSON REUTERS
·
18 Apr

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Business Wire
·
17 Apr

Aditxt Subsidiary Pearsanta Receives Irb Approval To Initiate Clinical Study Of Blood-Based Diagnostic For Endometriosis With Patient Enrollment Planned To Begin In May 2025

Reuters
·
16 Apr

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Business Wire
·
16 Apr

BRIEF-Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials

Reuters
·
14 Apr

Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

THOMSON REUTERS
·
14 Apr

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Business Wire
·
14 Apr